Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies

摘要

Background: In recent years, investigators have asserted that the 3+3 design lacks flexibility, making its use in modern early-phase trial settings, such as combinations and/or biological agents, inefficient. More innovative approaches are required to address contemporary research questions, such as those posed in trials involving immunotherapies.